Tag: mebendazole cancer therapy

Categories
Anti Cancer Cancer Research & Clinical Evidence Cancer Research Literacy Cancer Treatment & Clinical Research Cancer Treatment Claims & Critical Analysis Cancer Treatment Guidance Cancer Treatment Research & Critical Analysis Cancer Wellness Protocols Clinical Trials & Cancer Treatment Colorectal Cancer Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Fenbendazole Hulscher Study Integrative Oncology Insights Ivermectin Mebendazole Non-Chemo Cancer Treatments Pancreatic Cancer Repurposed Drug Studies Research News & Updates Wellness Company

NCI Ivermectin Research vs. the Hulscher Study: Two Completely Different Things

NCI and Hulscher Study Critique

Courage Against Cancer clarifies the distinction between the legitimate preclinical research conducted by the NCI on ivermectin and the controversial Hulscher observational study. The latter’s findings are compromised due to bias and conflicts of interest. Conflating the two may mislead patients, potentially exploiting their vulnerability and delaying effective treatments.

Categories
Anti Cancer Breakthrough Therapies Cancer Research & Clinical Evidence Cancer Support & Encouragement Cancer Treatment & Outcomes Cancer Treatment Guidance Cancer Wellness Protocols Clinical Trials & Cancer Treatment Colorectal Cancer Critical Evaluation of Cancer Research Drug Repurposing & Innovation Fenbendazole Gut-Microiome Health & Wellness Integrative Oncology Insights Ivermectin Joe Tippins Mebendazole Non-Chemo Cancer Treatments Repurposed Drug Studies Wellness Company

What Does an 84.4% ‘Clinical Benefit Rate’ Actually Mean — and What It Doesn’t

84 percent clinical benefit rate

Courage Against Cancer critiques the 2026 study by Hulscher et al., which claims an 84.4% clinical benefit rate from self-reported outcomes about off-label ivermectin and mebendazole in cancer patients. The study lacked control and independent verification, raising concerns over reliability and potential conflicts of interest. Caution is advised before drawing conclusions from such data.

Categories
Anti Cancer Cancer Support & Encouragement Cancer Treatment & Clinical Research Cancer Treatment Claims & Critical Analysis Cancer Treatment Options Cancer Wellness Protocols Clinical Trials & Cancer Treatment Drug Repurposing & Innovation Evaluating Cancer Treatment Claims Health & Wellness Hulscher Study Ivermectin Mebendazole Non-Chemo Cancer Treatments Repurposed Drug Studies Research & Science Wellness Company

The Wellness Company Study of Ivermectin and Mebendazole Review

Hulscher cohort study of Ivermectin and Mebendazole

A study conducted by Dr. Nicolas Hulscher at the Wellness Company examined the effects of compounded Ivermectin and Menebedazole on 197 cancer patients over six months. While results appear promising, concerns arise regarding the study’s methodology, raising questions about the necessity of formal clinical trials for FDA consideration.

Categories
Anti Cancer Cancer Treratments Community Impact Drug Repurposing & Innovation Guidelines Integrative Oncology Insights Non-Chemo Cancer Treatments Research News & Updates

The Importance of Asking Your Oncologist Questions About New Alternative Cancer Therapies

Jake the Koala weighs 10 questions to his oncologist

Before trying alternative or off-label cancer therapies like Ivermectin and Mebendazole, it’s crucial to talk with your oncologist. Learn the 10 essential questions every patient should ask to stay safe, informed, and empowered.

Categories
Anti Cancer cancer research Cancer Treratments drug repurposing Fenbendazole integrative-oncology Ivermectin Mebendazole Mission & Vision preclinical trial Repurposed Drug Studies Research & Science

From Promise to Proof: What Science Really Says About Ivermectin and Mebendazole in Cancer Treatment

Courage Against Cancer's Coco the Koala holding a fruit smoothie with a smile on her face

Courage Against Cancer announces a new preclinical research initiative studying ivermectin and mebendazole against ovarian cancer. Learn what science currently shows about these repurposed antiparasitic drugs — and why this research may change the future of cancer therapy.